AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33433656 — intervention group
Group type: COMPARATOR
Intervention: Integrative oncology treatment program (low adherence)
Number of subjects: 815
Study 32433835 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil (AL) - AL NanoCrystal Dispersion + oral aripiprazole 30 mg on day 1; AL 1,064 mg on day 8 and every 8 weeks thereafter
Number of subjects: 200
Study 32433835 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate (PP) - PP 234 mg on day 1; PP 156 mg on day 8 and then every 4 weeks thereafter
Number of subjects: 200
Study 35991136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound based on deep learning algorithm (BCNN-S)
Number of subjects: 80
Study 35991136 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound
Number of subjects: 80
Study 32565073 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline administered within 72 hours after tick removal
Number of subjects: 1689
Study 32565073 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1689
Study 32565073 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline
Number of subjects: 1689
Study 36164035 — intervention group
Group type: EXPERIMENTAL
Intervention: GDP (gemcitabine, dexamethasone, and cisplatin)
Number of subjects: 100
Study 36164035 — intervention group
Group type: COMPARATOR
Intervention: DHAP (dexamethasone, cytarabine, and cisplatin)
Number of subjects: 100
Study 36164035 — intervention group
Group type: EXPERIMENTAL
Intervention: GDP
Number of subjects: 100
Study 36164035 — intervention group
Group type: COMPARATOR
Intervention: DHAP
Number of subjects: 100
Study 33781979 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein of Marshall ethanol infusion
Number of subjects: 0
Study 33781979 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35537216 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intermittent theta-burst stimulation (iTBS)
Number of subjects: 42
Study 35537216 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta-burst stimulation (iTBS)
Number of subjects: 42
Study 32804911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 943
Study 32804911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study 34253805 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 244
Study 34253805 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-RECOSMO model
Number of subjects: 244
Study 34253805 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Life model
Number of subjects: 244
Study 34253805 — intervention group
Group type: EXPERIMENTAL
Intervention: FAS-CORRECT model
Number of subjects: 244
Study 34253805 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOURSE model
Number of subjects: 244
Study 33213514 — intervention group
Group type: EXPERIMENTAL
Intervention: AHT10s (applying hot towels for 10 s to the back)
Number of subjects: 50
Study 33213514 — intervention group
Group type: COMPARATOR
Intervention: Control (wiping only)
Number of subjects: 50
Study 32845371 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus surgery without anterior ciliary vessel preservation (Group A1)
Number of subjects: 60
Study 32845371 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus surgery with anterior ciliary vessel preservation (Group B1)
Number of subjects: 60
Study 32845371 — intervention group
Group type: COMPARATOR
Intervention: Corresponding nonsurgical eyes (Group A2 and B2)
Number of subjects: 60
Study 34788486 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia
Number of subjects: 32
Study 34788486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed trial (50 mmHg only during PECO)
Number of subjects: 32
Study 34788486 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 32
Study 32829304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) every 4 weeks (q4wk)
Number of subjects: 40
Study 32829304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) every 12 weeks (q12wk)
Number of subjects: 40
Study 32997826 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for pain on maximum jaw opening
Number of subjects: 282
Study 32997826 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for pain on palpation
Number of subjects: 282
Study 32997826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pain on maximum jaw opening and pain on palpation using DC/TMD
Number of subjects: 282
Study 33568585 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 140
Study 33568585 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-prepared platelet-rich fibrin (T-PRF)
Number of subjects: 140
Study 35536574 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH+) intervention plus enhanced usual care
Number of subjects: 627
Study 35536574 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care alone
Number of subjects: 627
Study 34843183 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5-25-50 mg/day)
Number of subjects: 0
Study 34843183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35419729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at 43 °C combined with acupuncture
Number of subjects: 63
Study 35419729 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion at 37 °C combined with sham acupuncture
Number of subjects: 63
Study 33904027 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (K-CIT) 40 mEq/day
Number of subjects: 80
Study 33904027 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 50 mg/day
Number of subjects: 80
Study 33233328 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline intervention (3 sessions per week, 30 min/session for 6 weeks)
Number of subjects: 27
Study 33111647 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE)
Number of subjects: 79
Study 33111647 — intervention group
Group type: COMPARATOR
Intervention: Relapse Prevention (RP)
Number of subjects: 79
Study 32628044 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS Heart System
Number of subjects: 0
Study 32628044 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33345885 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate adherence (greater than 80% of intended injections)
Number of subjects: 92
Study 33345885 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate adherence
Number of subjects: 92
Study 35841414 — intervention group
Group type: EXPERIMENTAL
Intervention: 19‐biomarker model (19‐BM)
Number of subjects: 147
Study 35841414 — intervention group
Group type: COMPARATOR
Intervention: PSA
Number of subjects: 147
Study 35841414 — intervention group
Group type: COMPARATOR
Intervention: PSA density (PSAD)
Number of subjects: 147
Study 35841414 — intervention group
Group type: COMPARATOR
Intervention: ERSPC‐3/4 risk calculator
Number of subjects: 147
Study 35841414 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of 19‐BM with clinical variables into diagnostic nomograms (DN)
Number of subjects: 147
Study 32891604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (HbA1c under 6.2%, blood pressure under 120/75 mmHg, low-density lipoprotein cholesterol under 80 mg/dL)
Number of subjects: 2540
Study 32891604 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (HbA1c under 6.9%, blood pressure under 130/80 mmHg, low-density lipoprotein cholesterol under 120 mg/dL)
Number of subjects: 2540
Study 34993588 — intervention group
Group type: EXPERIMENTAL
Intervention: No-stent group
Number of subjects: 90
Study 34993588 — intervention group
Group type: COMPARATOR
Intervention: Internal-stent group
Number of subjects: 90
Study 33053431 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Assistant Health Coaching (MA health coaching)
Number of subjects: 600
Study 33053431 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 33053431 — intervention group
Group type: EXPERIMENTAL
Intervention: MA health coaching
Number of subjects: 600
Study 32735422 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSI group: rolling the ipsilateral knee extensor muscles
Number of subjects: 27
Study 32735422 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRA group: rolling the contralateral muscles
Number of subjects: 27
Study 32735422 — intervention group
Group type: COMPARATOR
Intervention: Control group: sitting for 6 minutes relaxed
Number of subjects: 27
Study 35864718 — intervention group
Group type: EXPERIMENTAL
Intervention: CRRT with AN69-oXiris
Number of subjects: 16
Study 35864718 — intervention group
Group type: COMPARATOR
Intervention: CRRT with AN69-ST
Number of subjects: 16
Study 33992287 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 60
Study 33992287 — intervention group
Group type: COMPARATOR
Intervention: Neurodynamic Therapy (NDT)
Number of subjects: 60
Study 32534221 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg infusion
Number of subjects: 23
Study 36052897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of amiodarone diluted in 50 mL of 5% dextrose over 10 min
Number of subjects: 113
Study 36052897 — intervention group
Group type: COMPARATOR
Intervention: 50 mL of 5% dextrose over 10 min
Number of subjects: 113
Study 36052897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of amiodarone
Number of subjects: 113
Study 36052897 — intervention group
Group type: COMPARATOR
Intervention: 50 mL of 5% dextrose
Number of subjects: 113
Study 34061406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-grossing algorithm based on age, surgical approach, operation duration, biliary tract dilatation, and gallbladder gross anomalies
Number of subjects: 5663
Study 34061406 — intervention group
Group type: COMPARATOR
Intervention: Control group (390 randomly selected cases)
Number of subjects: 5663
Study 35511204 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 43
Study 33441917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 63
Study 33441917 — intervention group
Group type: COMPARATOR
Intervention: Control (dressing retention tape only)
Number of subjects: 63
Study 34605084 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted early support model
Number of subjects: 83032
Study 34605084 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 83032
Study 34589083 — intervention group
Group type: EXPERIMENTAL
Intervention: BLXA4 oral rinse
Number of subjects: 127
Study 34589083 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 127
Study 34589083 — intervention group
Group type: COMPARATOR
Intervention: No-rinse control
Number of subjects: 127
Study 34700571 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gene genomic classifier (GC) scores obtained from biopsy samples, assessed for distant metastases (DM), prostate cancer-specific mortality (PCSM), and overall survival (OS).
Number of subjects: 385
Study 34700571 — intervention group
Group type: COMPARATOR
Intervention: 22-gene genomic classifier (GC) score ≥ 0.45 (intermediate/high GC) compared to low GC.
Number of subjects: 385
Study 34700571 — intervention group
Group type: EXPERIMENTAL
Intervention: GC > 0.85 (threshold for inclusion in NRG GU009).
Number of subjects: 385
Study 34700571 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gene genomic classifier (GC) scores in patients receiving short-term or long-term androgen-deprivation therapy (ADT).
Number of subjects: 385
Study 35072987 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole leaf spinach intake
Number of subjects: 19
Study 35072987 — intervention group
Group type: EXPERIMENTAL
Intervention: Minced spinach intake
Number of subjects: 19
Study 35072987 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach intake (both treatments)
Number of subjects: 19
Study 35072987 — intervention group
Group type: COMPARATOR
Intervention: Control (no spinach intake)
Number of subjects: 19
Study 33668740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impulse-intensity group (LIG)
Number of subjects: 54
Study 33668740 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-impulse-intensity group (MIG)
Number of subjects: 54
Study 33668740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impulse-intensity group (HIG)
Number of subjects: 54
Study 33668740 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 54
Study 36215947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine + OPT-821
Number of subjects: 136
Study 36215947 — intervention group
Group type: COMPARATOR
Intervention: OPT-821 alone
Number of subjects: 136
Study 33323252 — intervention group
Group type: EXPERIMENTAL
Intervention: OL@‐OR@ mHealth programme (smartphone app and website)
Number of subjects: 726
Study 33323252 — intervention group
Group type: COMPARATOR
Intervention: Control version of the app (only collected baseline and outcome data)
Number of subjects: 726
Study 33323252 — intervention group
Group type: EXPERIMENTAL
Intervention: OL@‐OR@ mHealth programme
Number of subjects: 726
Study 33323252 — intervention group
Group type: COMPARATOR
Intervention: Control version of the app
Number of subjects: 726
Study 35040959 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64530440 750 mg once daily
Number of subjects: 20
Study 35040959 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64530440 750 mg twice daily
Number of subjects: 20
Study 35040959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34224930 — intervention group
Group type: EXPERIMENTAL
Intervention: GA-PCA (general anaesthesia with morphine patient-controlled analgesia)
Number of subjects: 18
Study 34224930 — intervention group
Group type: EXPERIMENTAL
Intervention: GA-LPB (general anaesthesia with lumbar plexus block)
Number of subjects: 18
Study 34224930 — intervention group
Group type: COMPARATOR
Intervention: S-LPB (spinal anaesthesia with lumbar plexus block)
Number of subjects: 18
Study 32824994 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster with a story of a PSP who benefitted from ICBT
Number of subjects: 132
Study 32824994 — intervention group
Group type: COMPARATOR
Intervention: Poster
Number of subjects: 132
Study 36084645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle therapy (energy restriction and exercise)
Number of subjects: 18
Study 32797740 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ProGlide suture-mediated vascular closure device
Number of subjects: 0
Study 32797740 — intervention group
Group type: COMPARATOR
Intervention: Two ProGlide suture-mediated vascular closure devices
Number of subjects: 0
Study 34647912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 75
Study 34647912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 32669521 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbascox® (800 mg/day) for 2 weeks
Number of subjects: 150
Study 32669521 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/day) for 2 weeks
Number of subjects: 150
Study 32669521 — intervention group
Group type: COMPARATOR
Intervention: Control group (watchful waiting)
Number of subjects: 150
Study 35897439 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) group
Number of subjects: 62
Study 35897439 — intervention group
Group type: COMPARATOR
Intervention: Textbook group
Number of subjects: 62
Study 32502908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 32502908 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 32502908 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study 33588150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gem/afatinib (Gem: 1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks; Afatinib: 40 mg orally once daily)
Number of subjects: 119
Study 33588150 — intervention group
Group type: COMPARATOR
Intervention: Gem alone (1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks)
Number of subjects: 119
Study 33588150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gem/afatinib
Number of subjects: 119
Study 33588150 — intervention group
Group type: COMPARATOR
Intervention: Gem alone
Number of subjects: 119
Study 33167909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen insufflation through the working channel during FOB intubation
Number of subjects: 36
Study 33167909 — intervention group
Group type: COMPARATOR
Intervention: No oxygen insufflation during FOB intubation
Number of subjects: 36
Study 36214868 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic CME transhiatal approach (CEM-TH, n=61)
Number of subjects: 99
Study 36214868 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic transhiatal (TH, n=38)
Number of subjects: 99
Study 32945103 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health messages + self-monitoring
Number of subjects: 156
Study 32945103 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological health messages + self-monitoring
Number of subjects: 156
Study 32945103 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 156
Study 32945103 — intervention group
Group type: COMPARATOR
Intervention: No messages
Number of subjects: 156
Study 34992255 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-CTx (FOLFIRINOX) plus bevacizumab/cetuximab
Number of subjects: 256
Study 34992255 — intervention group
Group type: COMPARATOR
Intervention: 2-CTx (FOLFOX or FOLFIRI) plus bevacizumab/cetuximab
Number of subjects: 256
Study 35227132 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 60
Study 35227132 — intervention group
Group type: COMPARATOR
Intervention: Inactive resting
Number of subjects: 60
Study 32949542 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg per month (with a 240 mg loading dose administered as two 120 mg injections) for 3 months
Number of subjects: 462
Study 32949542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 32949542 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 462
Study 32949542 — intervention group
Group type: COMPARATOR
Intervention: Galcanezumab and Placebo
Number of subjects: 462
Study 36288782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyson HEPA air purifier
Number of subjects: 50
Study 36288782 — intervention group
Group type: COMPARATOR
Intervention: Dummy filters (Placebo)
Number of subjects: 50
Study 34487828 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium protein (30%) diet
Number of subjects: 64
Study 34487828 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (35%) diet
Number of subjects: 64
Study 34487828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein (25%) diet
Number of subjects: 64
Study 34487828 — intervention group
Group type: COMPARATOR
Intervention: Control diet (35%)
Number of subjects: 64
Study 35940304 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTIS e‐learning module
Number of subjects: 87
Study 33068100 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 48
Study 33068100 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric Handgrip Training (IHG)
Number of subjects: 48
Study 33068100 — intervention group
Group type: COMPARATOR
Intervention: Unilateral, upper limb remote ischaemic preconditioning (RIPC)
Number of subjects: 48
Study 33068100 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 48
Study 35433976 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel surgical guide using CBCT and gypsum model scan
Number of subjects: 40
Study 35433976 — intervention group
Group type: COMPARATOR
Intervention: Freehand surgery using only CBCT data
Number of subjects: 40
Study 34372818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (IV + topical-TXA)
Number of subjects: 90
Study 34372818 — intervention group
Group type: COMPARATOR
Intervention: IV-TXA alone group
Number of subjects: 90
Study 32677707 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate (RT)
Number of subjects: 384
Study 32677707 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 384
Study 32371759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SBP target (<130 mmHg)
Number of subjects: 1263
Study 32371759 — intervention group
Group type: COMPARATOR
Intervention: Higher SBP target (130-149 mmHg)
Number of subjects: 1263
Study 32986097 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) group; instructed to eat ad libitum from 12:00 pm until 8:00 pm and abstain from caloric intake from 8:00 pm until 12:00 pm the following day
Number of subjects: 116
Study 32986097 — intervention group
Group type: COMPARATOR
Intervention: Consistent meal timing (CMT) group; instructed to eat 3 structured meals per day
Number of subjects: 116
Study 32986097 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) group (in-person cohort)
Number of subjects: 116
Study 32986097 — intervention group
Group type: COMPARATOR
Intervention: Comparison of appendicular lean mass index between groups
Number of subjects: 116
Study 35110687 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta-burst stimulation
Number of subjects: 268
Study 35110687 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency rTMS of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 268
Study 35110687 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 268
Study 33422006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative bevacizumab doses (various metrics including cumulative dose, quantiles of cumulative dose, standardized cumulative dose, Theoretical Blood Concentration (TBC), and Weighted Cumulative Exposure (WCE))
Number of subjects: 382